GIS:ETR
Gilead Sciences, Inc
133,50 €
arrow_upward
+0,45%(+0,60) 1D
14 հոկ, 14:42:08 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GIS...
Open
131,86 €
High
133,50 €
Low
131,78 €
Mkt. cap
185,82 մլրդ
Avg. vol.
805,00
Volume
65,00
52-wk high
136,24 €
52-wk low
98,96 €
No. of employees
17 հզր
Open
131,86 €
High
133,50 €
Low
131,78 €
Mkt. cap
185,82 մլրդ
Avg. vol.
805,00
Volume
65,00
52-wk high
136,24 €
52-wk low
98,96 €
No. of employees
17 հզր
News stories
From web sources and news partners
Reuters
·
23 րոպե առաջ
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Yahoo Finance
·
24 րոպե առաջ
Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors
Seeking Alpha
·
37 րոպե առաջ
Vir, Gilead ink licensing deal worth up to $1.9B (VIR:NASDAQ)
TipRanks
·
38 րոպե առաջ
Vir Biotechnology seals major oncology alliance with Gilead
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 հզր
Founded22 հնս, 1987 թ.
HeadquartersFoster City, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitegilead.com